What Drives the Clinical Benefits Seen with SGLT2 Inhibitors?
Feb 5, 2021 Volume, volume, volume may be the answer As findings from trial after trial provide evidence of the clinical benefit of SGLT2 inhibition in patients with reduced ejection fraction heart failure (HFrEF) — DAPA-HF, EMPIRE-HF, EMPEROR-Reduced, — there is little convincing left to do about the value of adding SGLT2 inhibitors to the HF armamentarium, as demonstrated by their inclusion in an updated expert decision pathway issued by the American College of Cardiology in early January 2021. But exactly why these drugs provide these demonstrable benefits is still debatable. Jesper Je...